Ligand Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Ligand Pharmaceuticals Incorporated

08/08/2023 23:02

* Ligand Pharmaceuticals Inc  LGND.OQ  reported quarterly
adjusted
earnings of $1.42​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was
for earnings of 64 cents per share.
    * Revenue fell 54.1% to $26.37 million from a year ago;
analysts
expected $25.73 million. 
    * Ligand Pharmaceuticals Inc's reported EPS for the quarter
was 13
cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.8%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Ligand Pharmaceuticals Inc shares had fallen by 8.0% this
quarter and lost 0.7% so far this year.
    * The company reported quarterly net income of $2.29
million.
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $103.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      0.64           1.42           Beat
 Mar. 31 2023      0.89           2.28           Beat
 Dec. 31 2022      1.19           1.36           Beat
 Sep. 30 2022      0.43           1.31           Beat